Complications of Penile Reconstruction Surgery Differ for Transgender Patients
The risks of penile reconstruction surgery (phalloplasty) appear higher in female-to-male transgender (transmale) patients undergoing gender confirmation surgery, compared to native male (cismale) patients undergoing phalloplasty for other reasons, reports a study in the February issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
Complications are also less frequent when reconstruction of the urethra (urethroplasty) is done as a single-stage procedure, according to the new research by ASPS Member Surgeon Jeffrey B. Friedrich, MD, of University of Washington, Seattle, and colleagues. "Our results provide useful information for surgeons and patients to consider when discussing options, risks, and expected outcomes of phalloplasty," Dr. Friedrich comments.
Increased Phalloplasty Risks for Transmale Patients and with Staged Urethral Surgery
Phalloplasty has important benefits not only for transmale patients undergoing gender confirmation surgery, but also for cismale patients who have lost their penis due to congenital or acquired disorders (for example, trauma). However, there are few data on the aggregate complications and outcomes of phalloplasty, including possible differences between these two groups of patients.
Dr. Friedrich and colleagues analyzed the findings of 50 previous studies relating to phalloplasty. Nineteen studies reported on phalloplasty in 869 transmale patients, while 31 studies reported on 482 cismale patients. The studies used a wide range of surgical approaches to phalloplasty, and assessed varying outcome measures.
The results showed some important differences in outcome between the two groups. The overall rate of complications related to the urethra was 39.4 percent in transmale patients compared to 24.8 percent in cismale patients. Rates of complications involving the tissue flaps used for penile reconstruction were also higher in transmale patients: 10.8 versus 8.1 percent.
Outcomes were also affected by the approach used to reconstruct the urethra: 23 studies including 723 patients used a single-step (primary) approach to urethroplasty, while 13 studies including 201 patients used multiple-step (staged) procedures. The rate of tissue flap-related complications was also lower with primary urethroplasty: 8.6 percent, compared to 16.7 percent for staged procedures.
In addition to fewer complications, single-stage urethral reconstruction was associated with improvement in key outcomes, for both transmale and cismale patients. Ability to urinate while standing, sexual functioning, and patient satisfaction were all better with primary versus staged urethroplasty.
In both transmale and cismale patients, penile reconstruction has important physical and psychosocial benefits. By synthesizing the results of previous studies, the new analysis provides much-needed information on the complications and outcomes of phalloplasty.
"Transmale patients seem to have a higher incidence of complications following phalloplasty than cismale patients," according to the authors. The higher rate of urethral complications in transmale patients likely reflects the inherent difficulties of reconstruction in this group of patients. The researchers note that the overall patient satisfaction rate was high: about 84 percent across groups.
"Overall, phalloplasty is an effective and efficacious technique, which benefits patients," Dr. Friedrich and colleagues conclude. They highlight the need for further prospective studies to understand the best options available to different groups of patients. They also call for the development of "standardized and reliable" tools for assessing patient-reported outcomes in transgender patients.
Click here to read "Outcomes after Phalloplasty: Do Transgender Patients and Multiple Urethral Procedures Carry a Higher Rate of Complication?"
Article: "Outcomes after Phalloplasty: Do Transgender Patients and Multiple Urethral Procedures Carry a Higher Rate of Complication?" (doi: 10.1097/PRS.0000000000004061)
About Plastic and Reconstructive Surgery
For more than 70 years, Plastic and Reconstructive Surgery® has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.
The American Society of Plastic Surgeons (ASPS) is the world's largest organization of board-certified plastic surgeons. Representing more than 7,000 Member Surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. ASPS comprises more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.